Trial Profile

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SON 1010 (Primary)
Indications Endometrial cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; First in man
Acronyms SB-101
Sponsors Sonnet BioTherapeutics Holdings, Inc

Most Recent Events

03 Feb 2026 The protocol has been amended to addition in treatment arm size.
03 Feb 2026 Planned End Date changed from 31 Dec 2024 to 30 Jun 2026.
03 Feb 2026 Planned primary completion date changed from 30 Dec 2024 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com